Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

Real-World Evaluation of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa

This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.

Inclusion Criteria:

• age ≥18 years
• diagnosis of moderate-to-severe HS with Hurley stage II or III
• Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules
• inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors

Exclusion Criteria:

• active infections (e.g., viral hepatitis, active tuberculosis)
• use of other biologics or systemic immunosuppressants within the past three months
• severe organ dysfunction (e.g., hepatic or renal failure)
• any other conditions that might affect study results